Seres Therapeutics Reports Positive SER-155 Phase 1b Study Results and Extends Cash Runway into 2026
Seres Therapeutics reported positive SER-155 Phase 1b results, showing improved epithelial integrity and reduced inflammation in stem cell transplant patients. Seres Therapeutics announced positive ...
– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo – – SER-109 was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback